Physician profile
Ayoola Gomih
NPI 1831117522
$20,186.75
in general payments reported to CMS, 2019-2025
15 companies · $777 in 2025
The $777 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,984 · 2020: $4,281 · 2021: $2,116 · 2022: $1,704 · 2023: $320 · 2024: $1,004 · 2025: $777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,208 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $829 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,208.12 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $829.00 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Great Lakes Medical Services, LLC | $16,917.00 | 2019-2024 | |
| Astellas Pharma US INC | $1,051.37 | 2019-2025 | Xtandi |
| Boston Scientific Corporation | $586.07 | 2019-2025 | Ams 700 |
| Endo Pharmaceuticals INC. | $570.40 | 2019-2024 | Xiaflex, Aveed |
| Pfizer INC. | $352.14 | 2019-2025 | |
| Endo USA, INC. | $188.04 | 2024-2025 | Xiaflex, Aveed |
| Sumitomo Pharma America, INC. | $137.39 | 2023-2025 | Orgovyx |
| Myovant Sciences INC. | $116.96 | 2021-2022 | |
| Progenics Pharmaceuticals, INC. | $64.82 | 2025 | |
| Abiomed | $44.35 | 2025 | |
| Phathom Pharmaceuticals, INC. | $42.18 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $37.96 | 2019-2025 | Erleada |
| Cardinal Health 414 LLC | $33.17 | 2023 | |
| Profound Medical Corp. | $22.83 | 2025 | Tulsa-Pro |
| Bayer Healthcare Pharmaceuticals INC. | $22.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$65,800.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayoola Gomih listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.